尿激酶合依达拉奉治疗急性脑梗塞临床观察  

EFFECT OF URIKINASE COMBINED WITH EDARAVONE IN TREATMENT OF ACUTE CEREBRAL INFARCTION

作　　者：昝立新[1] 

机构地区：[1]河南省三门峡市中心医院,三门峡472000

出　　处：《现代预防医学》2011年第6期1166-1168,共3页Modern Preventive Medicine

摘　　要：[目的]探讨尿激酶联合依达拉奉治疗急性脑梗塞的疗效。[方法]选择发病时间在3～6h内的脑梗塞患者108例,随机分为常规组、尿激酶组和联合用药组,3组同时给予控制脑水肿、改善微循环等治疗,尿激酶组在此基础上应用尿激酶100万U加入生理盐水100ml,30min内滴注完,联合用药组在尿激酶组基础上加用依达拉奉30mg加入生理盐水100ml滴注,对治疗前后患者的神经功能缺损进行评定,测定血清超氧化物歧化酶(SOD)和丙二醛(MDA)的含量以及统计再灌注发生率。[结果]经溶栓治疗的两组神经功能缺损评分明显低于常规组;与尿激酶组相比,联合用药组的SOD水平显著提高,MDA水平和再灌注发生率明显降低。[结论]尿激酶与依达拉奉合用治疗急性脑梗塞疗效显著,可有效防治再灌注的损伤。[Objective] To discuss the clinical efficacy of urokinase combined with edaravone on in the treatment of acute cerebral infarction. [ Methods ] 108 patients with onset time of cerebral infarction within 3 ～ 6h were randomly divided into the conventional group, urokinase group and the combined treatment group, three groups were all provided drug for conttolling cerebral edema and improving microcireulation. On the basis, urokinase group were provided 1 miLLion U urokinase with 100 ml saline and completed within 30 minute, the combination group in the UK group based were used of 30 mg edaravone withl00 nd normal saline; The neurological deficit of patients before and after treatment were assessed. The serum superoxide dismutase （SOD） and malondialdehyde （MDA） content were determined and incidence of repeffusion was calculated. [ Results] The neurological deficit scores in two groups by thrombolytic therapy were significantly lower than the conventional group; and the combined treatment group was significantly increased in SOD level, reduced in MDA level and incidence of reperfusion. [Con- clusion] The effectiveness of urokinase combined with edaravone on in the treatment of acute cerebral infarction was significant, and edaravone was effective in preventing repeffusion injury occurring after thrombolyt/c therapy/or acute cerebral infarction.

关 键 词：急性脑梗塞 溶栓 尿激酶 依达拉聿 

分 类 号：R743.33[医药卫生—神经病学与精神病学]